Almost a year ago, a group of scientists at Stanford and the Parker Institute for Cancer Immunotherapy published a paper in Nature Medicine that challenged a common assumption about where tumor fighting cells come from: While researchers had thought that the role of checkpoint blockade was to reinvigorate T cells already present in the tumor, they suggested that the vast majority actually didn’t come from the tumor sites at all.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,